After more than a decade with no change in the first-line systemic therapy for HCC, lenvatinib, a multikinase inhibitor of FGF1-4, VEGFR1-3, PDGFα, KIT, and RET, was approved for the first-line treatment of unresectable HCC. Here, PDGFA is linked to hepatocellular carcinoma.